Dexmethylphenidate hydrochloride is under clinical development by Cingulate and currently in Phase III for Attention Deficit Hyperactivity Disorder (ADHD). According to GlobalData, Phase III drugs for Attention Deficit Hyperactivity Disorder (ADHD) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dexmethylphenidate hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexmethylphenidate hydrochloride overview

Dexmethylphenidate hydrochloride is under development for the treatment of attention deficit hyperactivity disorder (ADHD). The drug candidate is administered orally and formulated as tablet. It is developed based on Cingulate’s innovative Precision Timed Release (PTR) drug delivery platform technology

Cingulate overview

Cingulate operates as a holding company. It develops drugs for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety associated disorders through its subsidiary. The company is headquartered in Kansas City, Kansas, the US.

For a complete picture of Dexmethylphenidate hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.